Skip to main content

Advertisement

SpringerLink
Log in

Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, approximately one-third of responders experience disease relapse following first-line therapy. Several studies have shown the efficacy of brentuximab vedotin (BV) in patients with relapsed/refractory HL. We present a retrospective analysis of 58 patients with relapsed/refractory HL treated with BV in a named patient program from 11 centers. The median follow-up duration was 20 (range, 4–84) months. The best overall response rate was 64% (complete response [CR], 31%; partial response [PR], 33%). The 5-year progression-free survival (PFS) and overall survival (OS) rates were 12% (95% confidence interval [CI], 0.05–0.22) and 26% (95% CI, 0.16–0.38), respectively. Among patients who achieved CR, the estimated 5-year PFS and OS rates were 32% (95% CI, 0.13–0.54) and 60% (95% CI, 0.33–0.78), respectively. A total of 26 patients underwent subsequent stem cell transplantation. The 5-year PFS and OS rates for 10 patients who had consolidative stem cell transplantation were 28% and 30%, respectively. Twenty-seven patients required further therapy following BV. At the time of the analysis, 12 patients (21%) were alive. Five patients (9%) had long-term remission after achieving CR with BV monotherapy, with a median PFS of 76 months. Three of them (5%) did not receive any other treatment following BV and their median PFS was 75 months. Our long-term results showed that a small subset of patients with relapsed/refractory cHL may benefit from and even be cured with BV monotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Goker H, Baslar Z, Ferhanoglu B (2015) Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol 94(3):415–420. https://doi.org/10.1007/s00277-014-2215-9

    Article  CAS  PubMed  Google Scholar 

  2. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128(12):1562–1566. https://doi.org/10.1182/blood-2016-02-699850

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pavone V, Mele A, Carlino D, Specchia G, Gaudio F, Perrone T, Mazza P, Palazzo G, Guarini A, Loseto G, Eleonora P, Cascavilla N, Scalzulli P, Melpignano A, Quintana G, Di Renzo N, Tarantini G, Capalbo S (2018) Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naive transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). Ann Hematol 97(10):1817–1824. https://doi.org/10.1007/s00277-018-3379-5

    Article  CAS  PubMed  Google Scholar 

  4. Perrot A, Monjanel H, Bouabdallah R, Quittet P, Sarkozy C, Bernard M, Stamatoullas A, Borel C, Bouabdallah K, Nicolas-Virelizier E, Fournier M, Morschhauser F, Brice P (2016) Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica 101(4):466–473. https://doi.org/10.3324/haematol.2015.134213

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P (2018) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. Hematol Oncol 36(1):174–181. https://doi.org/10.1002/hon.2383

    Article  CAS  PubMed  Google Scholar 

  6. Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL (2017) Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma. Oncotarget 8(53):91703–91710. https://doi.org/10.18632/oncotarget.18114

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gandolfi L, Pellegrini C, Casadei B, Stefoni V, Broccoli A, Tonialini L, Morigi A, Argnani L, Zinzani PL (2016) Long-term responders after brentuximab vedotin: single-center experience on relapsed and refractory Hodgkin lymphoma and anaplastic large cell lymphoma patients. Oncologist 21(12):1436–1441. https://doi.org/10.1634/theoncologist.2016-0112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Zagadailov EA, Corman S, Chirikov V, Johnson C, Macahilig C, Seal B, Dalal MR, Brockelmann PJ, Illidge T (2018) Real-world effectiveness of brentuximab vedotin versus physicians’ choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leuk Lymphoma 59(6):1413–1419. https://doi.org/10.1080/10428194.2017.1382698

    Article  CAS  PubMed  Google Scholar 

  9. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189. https://doi.org/10.1200/JCO.2011.38.0410

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Hematology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Murat Özbalak

  2. Department of Internal Medicine, Division of Hematology, Istanbul University Cerrahpaşa, Istanbul, Turkey

    Ayşe Salihoğlu & Teoman Soysal

  3. Division of Hematology, Antalya Medstar Hospital, Antalya, Turkey

    İhsan Karadoğan

  4. Department of Internal Medicine, Division of Medical Oncology, Cukurova University, Adana, Turkey

    Semra Paydaş

  5. Department of Oncology, Medicana International Hospital, Ankara, Turkey

    Evren Özdemir

  6. Department of Internal Medicine, Division of Medical Oncology, Gulhane Research and Training Hospital, Ankara, Turkey

    Birol Yıldız & Nuri Karadurmuş

  7. Department of Internal Medicine, Division of Hematology, Erciyes University, Kayseri, Turkey

    Leylagül Kaynar

  8. Department of Internal Medicine, Division of Hematology, Gazi University, Ankara, Turkey

    Münci Yagci

  9. Department of Internal Medicine, Division of Hematology, Uludag University, Bursa, Turkey

    Vildan Özkocaman

  10. Department of Internal Medicine, Division of Hematology, Ankara University, Ankara, Turkey

    Pervin Topçuoğlu & Muhit Özcan

  11. Division of Hematology, Anadolu Medical Center, Kocaeli, Turkey

    Elif Birtaş

  12. Department of Internal Medicine, Division of Hematology, Hacettepe University, Ankara, Turkey

    Hakan Göker

  13. Department of Hematology, Koc University School of Medicine and V.K.V. American Hospital, Istanbul, Turkey

    Burhan Ferhanoglu

Authors
  1. Murat Özbalak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayşe Salihoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teoman Soysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. İhsan Karadoğan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Semra Paydaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Evren Özdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Birol Yıldız
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nuri Karadurmuş
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Leylagül Kaynar
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Münci Yagci
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Vildan Özkocaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Pervin Topçuoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Muhit Özcan
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Elif Birtaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hakan Göker
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Burhan Ferhanoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Burhan Ferhanoglu.

Ethics declarations

Conflict of interest

BF is a member of advisory board of Takeda.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the central health authority (having approved the named patient program from the medical and ethical points of view), and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Özbalak, M., Salihoğlu, A., Soysal, T. et al. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. Ann Hematol 99, 301–307 (2020). https://doi.org/10.1007/s00277-019-03899-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03899-1

Keywords

Search

Navigation